Pregunta del mes | Kern Pharma Biologics

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche, Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy

0
0 / 5 (0 votos)

Cancer Cell

First published:  11 December 2017

DOI: http://dx.doi.org/10.1016/j.ccell.2017.11.002

Hanqiu Zheng, Yangjin Bae, Sabine Kasimir-Bauer, Rebecca Tang, Jin Chen, Guangwen Ren, Min Yuan, Mark Esposito, Wenyang Li, Yong Wei, Minhong Shen, Lanjing Zhang, Nikolai Tupitsyn, Klaus Pantel, Chadwick King, Jan Sun, Jodi Moriguchi, Helen Toni Jun, Angela Coxon, Brendan Lee, Yibin Kang

Background: Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells. 

SEGUIR LEYENDO